UBS Group
DMAA

UBS Group’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

UBS Group’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-38,159
Closed -$396K – 11530
2025
Q4 		$396K Buy
38,159
+18,038
+90% +$186K ﹤0.01% 6217
2025
Q3 		$207K Buy
20,121
+20,120
+2,012,000% +$206K ﹤0.01% 6649
2025
Q2 		$10 Buy
+1
New +$10 ﹤0.01% 10158

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.22% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group's DMAA Position: Q1 2026 in Review

UBS Group sold out of Drugs Made In America Acquisition Corp (DMAA) in Q1 2026, closing a stake of 38,159 shares — an estimated $396K sold.

UBS Group first reported a position in DMAA in Q2 2025 and held it in 3 quarters. The position peaked at $396K in Q4 2025. 39 funds tracked by Wall St. Rank hold DMAA as of Q1 2026.

  • UBS Group reported no remaining Drugs Made In America Acquisition Corp position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 38,159 Drugs Made In America Acquisition Corp shares in Q1 2026, an estimated $396K.
  • UBS Group first reported a position in Drugs Made In America Acquisition Corp in Q2 2025 and held it in 3 quarters.
  • UBS Group's Drugs Made In America Acquisition Corp position peaked at $396K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.